Natural killer cell–directed therapies: moving from unexpected results to successful strategies (original) (raw)
Herberman, R.B., Nunn, M.E., Holden, H.T. & Lavrin, D.H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer16, 230–239 (1975). CASPubMed Google Scholar
Long, E.O. Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol.17, 875–904 (1999). CASPubMed Google Scholar
Orange, J.S. & Ballas, Z.K. Natural killer cells in human health and disease. Clin. Immunol.118, 1–10 (2006). CASPubMed Google Scholar
Moretta, L. & Moretta, A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J.23, 255–259 (2004). CASPubMed Google Scholar
Cerwenka, A. & Lanier, L.L. Ligands for natural killer cell receptors: redundancy or specificity. Immunol. Rev.181, 158–169 (2001). CASPubMed Google Scholar
Walzer, T. et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc. Natl. Acad. Sci. USA104, 3384–3389 (2007). CASPubMed Google Scholar
Albertsson, P.A. et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol.24, 603–609 (2003). CASPubMed Google Scholar
Kim, S., Iizuka, K., Aguila, H.L., Weissman, I.L. & Yokoyama, W.M. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA97, 2731–2736 (2000). CASPubMed Google Scholar
Coca, S. et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer79, 2320–2328 (1997). CASPubMed Google Scholar
Chang, C.C., Campoli, M. & Ferrone, S. Classical and nonclassical HLA class I antigen and NK cell-activating ligand changes in malignant cells: current challenges and future directions. Adv. Cancer Res.93, 189–234 (2005). CASPubMed Google Scholar
Gasser, S., Orsulic, S., Brown, E.J. & Raulet, D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature436, 1186–1190 (2005). CASPubMedPubMed Central Google Scholar
Diefenbach, A., Jensen, E.R., Jamieson, A.M. & Raulet, D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature413, 165–171 (2001). CASPubMedPubMed Central Google Scholar
Vetter, C.S., Lieb, W., Brocker, E.B. & Becker, J.C. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br. J. Cancer91, 1495–1499 (2004). CASPubMedPubMed Central Google Scholar
Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature419, 734–738 (2002). CASPubMed Google Scholar
Imai, K., Matsuyama, S., Miyake, S., Suga, K. & Nakachi, K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet356, 1795–1799 (2000). CASPubMed Google Scholar
Hayashi, T. et al. Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res.66, 563–570 (2006). CASPubMed Google Scholar
Ferlazzo, G. et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med.195, 343–351 (2002). CASPubMedPubMed Central Google Scholar
Sivori, S. et al. Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J. Neuroimmunol.107, 220–225 (2000). CASPubMed Google Scholar
Fauriat, C. et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood109, 323–330 (2007). CASPubMed Google Scholar
Carrington, M. et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J. Exp. Med.201, 1069–1075 (2005). CASPubMedPubMed Central Google Scholar
Lopez-Vazquez, A. et al. Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Infect. Dis.192, 162–165 (2005). CASPubMed Google Scholar
Borg, C. et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest.114, 379–388 (2004). CASPubMedPubMed Central Google Scholar
Ghiringhelli, F., Menard, C., Martin, F. & Zitvogel, L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev.214, 229–238 (2006). CASPubMed Google Scholar
Orange, J.S. Human natural killer cell deficiencies. Curr. Opin. Allergy Clin. Immunol.6, 399–409 (2006). PubMed Google Scholar
Orange, J.S. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect.4, 1545–1558 (2002). CASPubMed Google Scholar
Bashirova, A.A., Martin, M.P., McVicar, D.W. & Carrington, M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu. Rev. Genomics Hum. Genet.7, 277–300 (2006). CASPubMed Google Scholar
Martin, M.P. et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet.31, 429–434 (2002). CASPubMed Google Scholar
Khakoo, S.I. et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science305, 872–874 (2004). CASPubMed Google Scholar
Gumá, M. et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood107, 3624–3631 (2006). PubMed Google Scholar
Hiby, S.E. et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med.200, 957–965 (2004). CASPubMedPubMed Central Google Scholar
Hanna, J. et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat. Med.12, 1065–1074 (2006). CASPubMed Google Scholar
Liu, R. et al. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J. Immunol.176, 5247–5254 (2006). CASPubMed Google Scholar
Zimmer, J., Bausinger, H. & de la Salle, H. Autoimmunity mediated by innate immune effector cells. Trends Immunol.22, 300–301 (2001). CASPubMed Google Scholar
Vollmer, T. et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet363, 1607–1608 (2004). CASPubMed Google Scholar
Van Kaer, L. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol.5, 31–42 (2005). CASPubMed Google Scholar
Bielekova, B. et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA103, 5941–5946 (2006). CASPubMed Google Scholar
Grimm, E.A., Mazumder, A., Zhang, H.Z. & Rosenberg, S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med.155, 1823–1841 (1982). CASPubMed Google Scholar
Rosenberg, S.A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med.313, 1485–1492 (1985). CASPubMed Google Scholar
Law, T.M. et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer76, 824–832 (1995). CASPubMed Google Scholar
Lotze, M.T. & Rosenberg, S.A. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer. Immunobiology172, 420–437 (1986). CASPubMed Google Scholar
Ueda, Y. et al. Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer. Hepatogastroenterology46 (suppl. 1), 1274–1279 (1999). CASPubMed Google Scholar
Burns, L.J. et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant.32, 177–186 (2003). CASPubMed Google Scholar
Kammula, U.S., White, D.E. & Rosenberg, S.A. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer83, 797–805 (1998). CASPubMed Google Scholar
Ghiringhelli, F. et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner. J. Exp. Med.202, 1075–1085 (2005). CASPubMedPubMed Central Google Scholar
Rodella, L. et al. Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells. Br. J. Haematol.115, 442–450 (2001). CASPubMed Google Scholar
Smyth, M.J. et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J. Exp. Med.200, 1325–1335 (2004). CASPubMedPubMed Central Google Scholar
Mortier, E. et al. Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ. Hyperagonist IL-15·IL-15Rα fusion proteins. J. Biol. Chem.281, 1612–1619 (2006). CASPubMed Google Scholar
Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science295, 2097–2100 (2002). CASPubMed Google Scholar
Giebel, S. et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood102, 814–819 (2003). CASPubMed Google Scholar
Miller, J.S. et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood109, 5058–5061 (2007). CASPubMedPubMed Central Google Scholar
Davies, S.M. et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood100, 3825–3827 (2002). CASPubMed Google Scholar
Farag, S.S. et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol. Blood Marrow Transplant.12, 876–884 (2006). CASPubMed Google Scholar
Aversa, F. et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med.339, 1186–1193 (1998). CASPubMed Google Scholar
Cooley, S. et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood106, 4370–4376 (2005). CASPubMedPubMed Central Google Scholar
Passweg, J.R., Stern, M., Koehl, U., Uharek, L. & Tichelli, A. Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant.35, 637–643 (2005). CASPubMed Google Scholar
Passweg, J.R. et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia18, 1835–1838 (2004). CASPubMed Google Scholar
Miller, J.S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood105, 3051–3057 (2005). CASPubMed Google Scholar
Delahaye, N.F., Barbier, M., Fumoux, F. & Rihet, P. Association analyses of NCR3 polymorphisms with P. falciparum mild malaria. Microbes Infect.9, 160–166 (2007). CASPubMed Google Scholar
Ljunggren, H.G. & Malmberg, K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol.7, 329–339 (2007). CASPubMed Google Scholar
Bryceson, Y.T., March, M.E., Ljunggren, H.G. & Long, E.O. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood107, 159–166 (2006). CASPubMedPubMed Central Google Scholar
Koh, C.Y. et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood97, 3132–3137 (2001). CASPubMed Google Scholar
Sheridan, C. First-in-class cancer therapeutic to stimulate natural killer cells. Nat. Biotechnol.24, 597 (2006). CASPubMed Google Scholar
Carter, P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol.6, 343–357 (2006). CASPubMed Google Scholar
Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood99, 754–758 (2002). CASPubMed Google Scholar
Weng, W.K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol.21, 3940–3947 (2003). CASPubMed Google Scholar
Khan, K.D. et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin. Cancer Res.12, 7046–7053 (2006). CASPubMed Google Scholar
Shahied, L.S. et al. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J. Biol. Chem.279, 53907–53914 (2004). CASPubMed Google Scholar
Uherek, C. et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood100, 1265–1273 (2002). CASPubMed Google Scholar
Smyth, M.J. et al. Nature's TRAIL–on a path to cancer immunotherapy. Immunity18, 1–6 (2003). CASPubMed Google Scholar
Daniel, D. et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood110, 4037–4046 (2007). CASPubMed Google Scholar
Taieb, J. et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med.12, 214–219 (2006). CASPubMed Google Scholar
Vosshenrich, C.A. et al. CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J. Exp. Med.204, 2569–2578 (2007). CASPubMedPubMed Central Google Scholar
Blasius, A.L., Barchet, W., Cella, M. & Colonna, M. Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells. J. Exp. Med.204, 2561–2568 (2007). CASPubMedPubMed Central Google Scholar
Caminschi, I. et al. Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J. Exp. Med.204, 2579–2590 (2007). CASPubMedPubMed Central Google Scholar
Chan, C.W. et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med.12, 207–213 (2006). CASPubMed Google Scholar
Bonmort, M. et al. Interferon-γ is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC). Biochimie89, 872–877 (2007). CASPubMed Google Scholar
Mailliard, R.B. et al. α-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res.64, 5934–5937 (2004). CASPubMed Google Scholar
Osada, T., Clay, T., Hobeika, A., Lyerly, H.K. & Morse, M.A. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol. Immunother.55, 1122–1131 (2006). PubMed Google Scholar
Andre, F. et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol.172, 2126–2136 (2004). CASPubMed Google Scholar
Chaput, N. et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J. Immunol.172, 2137–2146 (2004). CASPubMed Google Scholar
Taieb, J. et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J. Immunol.176, 2722–2729 (2006). CASPubMed Google Scholar
Chaput, N. et al. Dendritic cell derived-exosomes: biology and clinical implementations. J. Leukoc. Biol.80, 471–478 (2006). CASPubMed Google Scholar
Pilla, L. et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients. Cancer Immunol. Immunother.55, 958–968 (2006). CASPubMed Google Scholar
Sivori, S. et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc. Natl. Acad. Sci. USA101, 10116–10121 (2004). CASPubMed Google Scholar
Krieg, A.M., Efler, S.M., Wittpoth, M., Al Adhami, M.J. & Davis, H.L. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother.27, 460–471 (2004). CASPubMed Google Scholar
Link, B.K. et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother.29, 558–568 (2006). CASPubMed Google Scholar
Kanzler, H., Barrat, F.J., Hessel, E.M. & Coffman, R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med.13, 552–559 (2007). CASPubMed Google Scholar
Whiteside, T.L. & Friberg, D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am. J. Med.105, 27S–34S (1998). CASPubMed Google Scholar
Brandau, S. et al. NK cells are essential for effective BCG immunotherapy. Int. J. Cancer92, 697–702 (2001). CASPubMed Google Scholar
Davies, F.E. et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood98, 210–216 (2001). CASPubMed Google Scholar
Brune, M. et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood108, 88–96 (2006). CASPubMed Google Scholar
Ghiringhelli, F. et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother.56, 641–648 (2007). CASPubMed Google Scholar
Ishikawa, A. et al. A phase I study of α-galactosylceramide (KRN7000)–pulsed dendritic cells in patients with advanced and recurrent non–small cell lung cancer. Clin. Cancer Res.11, 1910–1917 (2005). CASPubMed Google Scholar
Motohashi, S. et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res.12, 6079–6086 (2006). CASPubMed Google Scholar
Mazodier, K. et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood106, 3483–3489 (2005). CASPubMedPubMed Central Google Scholar
Kim, M.H. et al. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors. J. Immunol.164, 5883–5889 (2000). CASPubMed Google Scholar
Atkins, M.B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17, 2105–2116 (1999). CASPubMed Google Scholar
Bukowski, R.M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer80, 1198–1220 (1997). CASPubMed Google Scholar
Meropol, N.J. et al. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol. Immunother.46, 318–326 (1998). CASPubMed Google Scholar
Meseri, A. et al. Natural-killer cell activity and cytogenetic response in chronic myelogenous leukemia treated with alpha-interferon. Br. J. Haematol.78, 585–586 (1991). CASPubMed Google Scholar
de Castro, F.A. et al. Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk. Lymphoma44, 2061–2067 (2003). CASPubMed Google Scholar
Gollob, J.A. et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin. Cancer Res.6, 1678–1692 (2000). CASPubMed Google Scholar
Robertson, M.J. et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res.5, 9–16 (1999). CASPubMed Google Scholar
Gollob, J.A. et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol.21, 2564–2573 (2003). PubMed Google Scholar
Robertson, M.J. et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res.12, 4265–4273 (2006). CASPubMed Google Scholar
Davis, I.D. et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res.13, 3630–3636 (2007). CASPubMed Google Scholar
Chen, W. et al. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function. Biol. Blood Marrow Transplant.11, 23–34 (2005). CASPubMed Google Scholar
Pilla, L. et al. Natural killer and NK-like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. Cancer Res.65, 3942–3949 (2005). CASPubMed Google Scholar
Mazzaferro, V. et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res.9, 3235–3245 (2003). CASPubMed Google Scholar
McHutchison, J.G. et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology46, 1341–1349 (2007). CASPubMed Google Scholar
Escudier, B. et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J. Transl. Med.3, 10 (2005). PubMedPubMed Central Google Scholar
Gluck, W.L. et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res.10, 2253–2264 (2004). CASPubMed Google Scholar
Berdeja, J.G. et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin. Cancer Res.13, 2392–2399 (2007). CASPubMed Google Scholar
Parihar, R. et al. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon γ production in a subset of patients. Clin. Cancer Res.10, 5027–5037 (2004). CASPubMed Google Scholar
Renner, C. et al. Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody. Cancer Immunol. Immunother.49, 173–180 (2000). CASPubMed Google Scholar
Hartmann, F. et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin. Cancer Res.7, 1873–1881 (2001). CASPubMed Google Scholar
Li, Z., Lim, W.K., Mahesh, S.P., Liu, B. & Nussenblatt, R.B. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56bright regulatory NK cells in patients with active uveitis. J. Immunol.174, 5187–5191 (2005). CASPubMed Google Scholar